Author

Erik Ramon‐Gil

Newcastle UniversityORCID 0000-0002-6397-0130Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Derek A. ManniD· 3 shared Jack LeslieiD· 3 shared A. CarteriD· 1 shared A. L. CollinsiD· 1 shared Ahmed Omar KasebiD· 1 shared Alessandro ParisiiD· 1 shared Alistair EastoniD· 1 shared Andrea DalbeniiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Derek A. MannORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyScience AdvancesPeer-reviewedMar 11, 2026

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis

Bruno Beernaert, Rose L. Jady‐Clark, Parin Shah…·Eileen E. Parkes

This study shows that chromosomal instability in esophageal adenocarcinoma drives an inflammatory tumor microenvironment through a cGAS-chemokine-myeloid axis, with CXCL8 as a key mediator.

11 citationstop 1%

humanspatial transcriptomics

Cancer BiologybioRxivPreprintJul 8, 2025

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Pasquale Lombardi, Erik Ramon‐Gil, Leonardo Brunetti…·David James Pinato

This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.

DOI 10.1101/2025.07.08.663653

humanbulk RNA-seq

Cancer BiologybioRxivPreprintSep 16, 2024

Ex-vivo mouse precision cut tumour slices for modelling hepatocellular carcinoma; A 3Rs solution for at-scale drug screening

A. L. Collins, Keara Kirkness, Erik Ramon‐Gil…·Jack Leslie

This paper develops an ex-vivo model of hepatocellular carcinoma using precision-cut tumour slices to enable efficient and ethical drug screening.

DOI 10.1101/2024.09.16.613213

mouseexperimental assay